The China National Medical Products Administration (NMPA) has granted clinical trial approval to ABBV-706, a novel antibody-drug conjugate (ADC) developed by AbbVie (NYSE: ABBV), for the treatment of relapsed/refractory small cell lung cancer (SCLC) and other neuroendocrine tumors .
ABBV-706 is a targeted therapy that binds to SEZ6, a protein overexpressed in many SCLCs and neuroendocrine cancers. The drug utilizes a topoisomerase 1 (Top1) inhibitor payload, which is designed to induce DNA damage and cell death in cancer cells. The decision by the NMPA follows positive results from a Phase I study, where ABBV-706 demonstrated a manageable safety profile and showed promising anti-tumor activity in heavily pretreated patients with SCLC and neuroendocrine tumors .- Flcube.com
